Thirty-eight patients with metastatic colorecal carcinoma were treated with 5-fluorouracil (5-FU), and 38 patients were treated with the combination of 5-FU, cyclophosphamide, and methotrexate. In terms of percent response, response duration, and survival there was no apparent difference between the
Different dose regimens of 5-fluorouracil and interferon-α in patients with metastatic colorectal carcinoma
✍ Scribed by P. Ragnhammar; H. Blomgren; D. Edler; G. Lundell; I. Magnusson; T. Sonnenfeld
- Book ID
- 116166170
- Publisher
- Elsevier Science
- Year
- 1995
- Tongue
- English
- Weight
- 688 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Background: Colorectal carcinoma is the third leading cause of cancer-related death. the primary treatment for patients with metastatic colorectal carcinoma is systemic chemotherapy with 5-fluorouracil (5-fu) and leucovorin (lv), a biomodulator of 5-fu that has been shown to enhance its activity
disease progression. IFN was administered subcutaneously three times weekly at for the Groupe d'Etude et de a dose of 3 MU (body surface area [BSA] õ 1.75 m 2 ) or 4.5 MU (BSA ¢ 1.75 m 2 ). Recherche sur les Cancers de RESULTS. World Health Organization toxicity Grade 3-4 occurred in 21 patients l'O